Brief: NovaBridge Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric Cancer
16/03/2026 11:36
March 16 (Reuters) - NovaBridge Biosciences NBP.O: NOVABRIDGE ANNOUNCES PRODUCTIVE FDA TYPE B MEETING ON POTENTIAL ACCELERATED APPROVAL PATHWAY FOR GIVASTOMIG IN GASTRIC CANCER NOVABRIDGE BIOSCIENCES - FDA CONFIRMS GIVASTOMIG ELIGIBLE FOR ACCELERATED APPROVAL PATHWAY NOVABRIDGE BIOSCIENCES - TO INITIATE REGISTRATIONAL PHASE 3 COMBINATION TRIAL IN Q4 2026 USING ORR AS PRIMARY ENDPOINT Source text: ID:nGNX4zrx9d Further company coverage: NBP.O ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview